Related Experiment Video
Updated: Mar 18, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
Alain Cohen Solal1, François Tournoux1, Florence Beauvais1
1Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris, Université Denis Diderot, INSERM U942, Paris, France.
Insights
Heart failure with preserved ejection fraction is now the most common type due to population aging. Current treatments lack proven efficacy, despite ongoing research into therapies like renin-angiotensin system antagonists.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent, driven by an aging global population.
- HFpEF is now the most frequent presentation of heart failure, surpassing other forms.
- The prognosis of HFpEF is comparable to that of heart failure with reduced ejection fraction.
Purpose:
- To review the epidemiologic, diagnostic, pathophysiologic, and therapeutic aspects of heart failure with preserved ejection fraction.
- To highlight the diagnostic utility of B-type natriuretic peptide levels and Doppler echocardiography.
- To discuss the current limitations in effective treatment strategies for HFpEF.
Summary:
- HFpEF is the predominant form of heart failure in aging populations.
- Diagnosis relies on B-type natriuretic peptide levels and Doppler echocardiography.
- Effective therapeutic options remain limited, though renin-angiotensin system antagonists show potential.
Impact:
- Provides a comprehensive overview of HFpEF for clinicians and researchers.
- Emphasizes the need for further clinical trials to identify effective treatments.
- Contributes to understanding the management of a growing cardiovascular disease burden.
Abstract:
The concept of heart failure with preserved left ventricular ejection fraction has replaced that of diastolic heart failure. It is today the most frequent presentation of heart failure because of the progressive aging of the population. Its prognosis appears to be similar to that of heart failure with reduced systolic function. B type natriuretic peptide dosing as well as doppler-echocardiography are useful for the diagnosis. Today, no treatment has revealed effective but clinical trials have been scarce. Renin-angiotensin system antagonists have promising properties but haven't shown efficacy. This article reviews the epidemiologic, diagnostic, pathophysiologic and therapeutic aspects of the disease.
